TICKERNERD
Menu
SRRKSRRKHealthcare · Biotechnology

SRRK Stock Forecast: Scholar Rock Holding Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$57
+2.26% on the day

The 18 Wall Street analysts covering Scholar Rock Holding Corp. hold a median 12-month price target of $60 — +6.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.9B
Ticker Nerd rank
32 / 100
Median analyst target
$60
Analysts covering
18
Total return, dividends reinvested
1W
+7.6%
1M
+11.0%
YTD
+28.3%
1Y
+63.3%
From 52W high
−2.5%
From 52W low
+102.4%
$28
$58
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRRK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scholar Rock Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Accruals
74
Value
71
Volatility
52
Revisions
41
Growth
35
Quality
25
Size
20
Issuance
7

Momentum (83): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRRK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRRK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26SRRKHigh $76Median $60Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says18 analysts
18 Buy0 Hold0 Sell
Low $48Median $60High $76

The green dot is the last close — the median target sits +6.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026JP MorganMaintainsOverweight$56 → $63
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$65
10 Aug 2026WedbushReiteratesOutperform$58
7 Aug 2026CitigroupMaintainsBuy$58 → $60
21 July 2026WedbushReiteratesOutperform$58
21 July 2026WedbushReiteratesOutperform—
8 May 2026BarclaysMaintainsOverweight—
8 May 2026BarclaysMaintainsOverweight$53 → $55
8 May 2026HC Wainwright & Co.MaintainsBuy—
8 May 2026HC Wainwright & Co.MaintainsBuy$58 → $65
21 Apr 2026Canaccord GenuityInitiatesBuy—
1 Apr 2026WedbushMaintainsOutperform—
16 Mar 2026JP MorganMaintainsOverweight—
4 Mar 2026BarclaysMaintainsOverweight—
4 Mar 2026BMO CapitalMaintainsOutperform—
4 Mar 2026CitigroupMaintainsBuy—
4 Mar 2026Piper SandlerMaintainsOverweight—
4 Mar 2026Truist SecuritiesMaintainsBuy—
3 Mar 2026HC Wainwright & Co.ReiteratesBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRRK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SRRK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

Scholar Rock Holding Corp. (SRRK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.2×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
27.1×

Cheaper than 4% of US stocks

EV / EBITDA
−16.3×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−167.8%

Higher than 8% of US stocks

Return on assets
−58.8%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SRRK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRRKScholar Rock Holding Corp.$6.9B
32
CGONCG Oncology, Inc.$7.0B
18
ORKAOruka Therapeutics, Inc.$7.1B
41
CAICaris Life Sciences, Inc.$7.4B
31
COGTCogent Biosciences, Inc.$6.3B
35
MIRMMirum Pharmaceuticals, Inc.$6.3B
69
RYTMRhythm Pharmaceuticals, Inc.$7.6B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scholar Rock Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRRK news & analysis

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Business Wire · 21 Aug 2026neutral

Scholar Rock announced it has removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for treating spinal muscular atrophy (SMA), as part of an update on global regulatory progress across the U.S., Europe, and Japan.

Why it matters — SRRK watchers would care because this regulatory update affects the company's apitegromab BLA filing and its global commercialization plans for treating SMA.

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

MarketBeat · 17 Aug 2026neutral

Scholar Rock CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing facility.

Why it matters — A scheduled FDA decision date for apitegromab marks a key regulatory milestone for Scholar Rock's lead SMA candidate.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 14 Aug 2026neutral

Scholar Rock announced it granted inducement equity awards to twelve newly hired employees, comprising inducement stock options for 14,889 shares and inducement restricted stock units for 37,058 shares of common stock, covering an aggregate of 51,947 shares under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement grants signal ongoing hiring and equity compensation activity at Scholar Rock, which SRRK watchers may note as a routine corporate governance disclosure.

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Business Wire · 7 Aug 2026positive

Scholar Rock announced that the FDA review of its apitegromab Biologics License Application for the treatment of children and adults with spinal muscular atrophy is progressing with the company's second fill-finish facility. An approval decision is anticipated by the September 30, 2026 action date.

Why it matters — A SRRK watcher would care because this marks ongoing FDA progress on a key regulatory milestone for apitegromab, with a decision timeline now set for late 2026.

FAQ

Frequently asked questions about SRRK stock

What is the SRRK stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Scholar Rock Holding Corp. have a median 12-month price target of $60, with estimates ranging from $48 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRRK stock a buy right now?

Of the 18 analysts covering Scholar Rock Holding Corp., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scholar Rock Holding Corp. 32 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRRK?

As at 22 Aug 2026, Scholar Rock Holding Corp. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will SRRK stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +6.2% from the last close, and Ticker Nerd's factor model ranks Scholar Rock Holding Corp. 32 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRRK stock forecast for 2030?

No analyst covering Scholar Rock Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRRK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $76 over the next 12 months.

How has SRRK stock performed over the past year?

Scholar Rock Holding Corp. returned +63.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Scholar Rock Holding Corp. do?

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases where protein growth factor signaling plays a central role. It employs a proprietary platform targeting the transforming growth factor beta (TGFβ) superfamily to create monoclonal antibodies that selectively inhibit precursor activation of these growth factors.

What is the latest news on SRRK?

The most recent item we track (Business Wire, 21 Aug 2026): "Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan". Scholar Rock announced it has removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for treating spinal muscular atrophy (SMA), as part of an update on global regulatory progress across the U.S., Europe, and Japan.

Company

About Scholar Rock Holding Corp.

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases where protein growth factor signaling plays a central role. It employs a proprietary platform targeting the transforming growth factor beta (TGFβ) superfamily to create monoclonal antibodies that selectively inhibit precursor activation of these growth factors. Key product candidates include apitegromab, a selective anti-latent myostatin antibody in Phase 3 for spinal muscular atrophy in patients aged two years and older, with additional Phase 2 programs in spinal muscular atrophy for younger patients and facioscapulohumeral muscular dystrophy, plus preclinical efforts in other neuromuscular diseases. The pipeline also features SRK-181 in Phase 1 for immuno-oncology in cancers resistant to checkpoint inhibitors, SRK-373 in preclinical for fibrotic diseases, and SRK-256 in preclinical for iron-restricted anemia. Scholar Rock Holding Corporation operates in the biotechnology sector, addressing neuromuscular disorders, obesity, cancer, fibrosis, and hematology through this novel approach. Founded in 2012 and headquartered in Cambridge, Massachusetts, it manages its activities as a single operating segment dedicated to advancing these investigational therapies.

CEO Mr. David L. Hallal · 289 employees · United States · https://www.scholarrock.com